+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Immunohistochemical staining of dystrophin on formalin-fixed paraffin-embedded sections in Duchenne/Becker muscular dystrophy and manifesting carriers of Duchenne muscular dystrophy



Immunohistochemical staining of dystrophin on formalin-fixed paraffin-embedded sections in Duchenne/Becker muscular dystrophy and manifesting carriers of Duchenne muscular dystrophy



Neuromuscular Disorders 10(6): 425-429



We succeeded in immunostaining of monoclonal anti-dystrophin antibodies on formalin-fixed and paraffin-embedded muscle sections from patients with Duchenne muscular dystrophy, patients with Becker muscular dystrophy, and manifesting carriers of Duchenne muscular dystrophy using Catalyzed Signal Amplification(TM) system. The Catalyzed Signal Amplification system is an extremely sensitive immunohistochemistry staining procedure based on the peroxidase-catalyzed deposition of a biotinylated phenolic compound. We used three mouse monoclonal antibodies: DYS1, DYS2, and DYS3. Muscle sections were treated using the Target Retrieval Solution(TM) and the Catalyzed Signal Amplification system. In control patients, DYS1 and DYS2 were stained at the sarcolemma, but DYS3 remained unstained. In Duchenne muscular dystrophy patients, DYS1 and DYS2 staining were undetected. In Becker muscular dystrophy patients, the immunolabeling of DYSI and DYS2 were weak and discontinuous. In manifesting carriers of Duchenne muscular dystrophy, DYS1 and DYS2 staining showed a mosaic pattern of dystrophin-positive fibers and dystrophin-negative fibers. DYS1 and DYS2 staining patterns of this study are similar to those of frozen sections using conventional methods previously reported. In cases from whom frozen muscle sections cannot be obtained, immunohistochemical dystrophin analysis using the Catalyzed Signal Amplification system will be beneficial for the diagnosis and the screening of neuromuscular diseases.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 046335039

Download citation: RISBibTeXText

PMID: 10899449

DOI: 10.1016/s0960-8966(99)00116-9


Related references

Dystrophin analysis in carriers of Duchenne and Becker muscular dystrophy. Neurology 65(12): 1984-1986, 2005

Usefulness of test: manual muscle testing, goniometry, and daily activities for differential diagnosis of Duchenne muscular dystrophy, Becker's mild muscular dystrophy and Becker's severe muscular dystrophy. International Journal of Rehabilitation Research. Internationale Zeitschrift für Rehabilitationsforschung. Revue Internationale de Recherches de Readaptation 21(1): 79-85, 1998

A survey of manifesting carriers of duchenne and becker muscular dystrophy in wales uk. Clinical Genetics 36(1): 31-37, 1989

Genetic analysis of 60 Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD) patients using dystrophin cDNA. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Academiae Medicinae Sinicae 15(6): 399-404, 1993

Partial deficiency of dystrophin in manifesting duchenne muscular dystrophy carriers. American Journal of Human Genetics 43(3 Suppl.): A172, 1988

Dystrophin-associated protein abnormalities in dystrophin-deficient muscle fibers from symptomatic and asymptomatic Duchenne/Becker muscular dystrophy carriers. Acta Neuropathologica. 92(4): 369-377, 1996

Signs and symptoms of Duchenne muscular dystrophy and Becker muscular dystrophy among carriers in the Netherlands: A cohort study. Lancet (North American Edition) 353(9170): 2116-2119, 1999

Histological and immunohistochemical analysis of dystrophin++ in muscular dystrophy of Duchenne and Becker type. Revista de Neurologia 23(Suppl. 3): S395-S399, 1995

Specific features of Becker Muscular Dystrophy patients and female carriers of Duchenne Muscular Dystrophy. Archives de Pediatrie 22(12 Suppl 1): 12s31-6, 2015

Immunohistochemical analysis of dystrophin-associated proteins in Becker/Duchenne muscular dystrophy with huge in-frame deletions in the NH2-terminal and rod domains of dystrophin. Journal of Clinical Investigation 93(1): 99-105, 1994

Variability in clinical, genetic and protein abnormalities in manifesting carriers of Duchenne and Becker muscular dystrophy. Neuromuscular Disorders 3(1): 57-64, 1993

Dystrophin analysis in Duchenne and Becker muscular dystrophy carriers: correlation with intracellular calcium and albumin. Annals of Neurology 28(5): 674-679, 1990

Identifying deletions in the dystrophin gene and detecting carriers in families with Duchenne's/Becker's muscular dystrophy. Revista de Neurologia 48(2): 66-70, 2009

Direct carriers detection in Duchenne/Becker muscular dystrophy families with deletions in the dystrophin gene. European Journal of Human Genetics 6(Suppl. 1): 122, 1998

Intragenic deletions in 21 Duchenne muscular dystrophy (DMD)/Becker muscular dystrophy (BMD) families studied with the dystrophin cDNA: location of breakpoints on HindIII and BglII exon-containing fragment maps, meiotic and mitotic origin of the mutations. American Journal of Human Genetics 43(5): 620-629, 1988